Carrillo-Esper R, Sánchez-García R, Jiménez-Morales EE

Idioma: Español
Referencias bibliográficas: 29
Paginas: 139-145
Archivo PDF: 619.42 Kb.

RESUMEN

Las ciclodextrinas son moléculas formadas por varias moléculas de glucosa cuya estructura semeja un anillo, con una capa externa hidrofílica y una porción interna lipofílica, que tridimensionalmente adopta la forma de una dona. El sugammadex es una ciclodextrina modificada diseñada para encapsular agentes relajantes musculares no despolarizantes aminoesteroideos. Ha sido estudiada en modelos animales y estudios clínicos en donde se ha demostrado su efectividad y margen de seguridad. El sugammadex se une al agente bloqueador neuromuscular y lo encapsula, haciendo innecesario el uso de inhibidores de colinesterasa. Por su innovador mecanismo de acción y relativa carencia de efectos colaterales su inclusión en el armamentario terapéutico del anestesiólogo impactará en la práctica cotidiana de la anestesiología. El objetivo de este trabajo es revisar los conceptos actuales sobre el sugammadex.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bom A, Cameron K, Clark JK. Chemical chelation as a novel method of NMB reversal: discovery of Org 25969 [abstract). Eur J Anesthesiol 200l;18:99.

2. Bom A, Bradley M, Camuron K. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic-host. Angew Chemv Int Ed Engl 2002;41:266-270.

3. Alvarez GJA. Muscle reluxants: novelties and future development. Anaesthesiologie and Reanimation 2002;12:95-98.

4. Adam M, Bennetl DJ, Bon A. Cyciodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity. J Med Chem 2002;45:1806-1816.

5. Tarver GJ, Grove SJA, Buehanan K. 2-0-Substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg Med Chem 2002;10:1819-27.

6. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003:632-637.

7. Zhang MQ. Drug specific cyclodextrins: the future of rapid neuromuscular block reversal. Drugs Future 2003;28:347-354.

8. Bom A, Mason R, Mclndewar L. Org 25969 causes rapid reversal of rocuronium-induced neuromuscular block, independent of acid-base status (abstract) Anesthesiology 2002:A-1009.

9. Fielding S, Cameron L. MRI diffusion coefficient study of steroid cyclodextrin complexes. Magn Reson Chem 2002;40:S106-S109.

10. Ploeger BA, Ruigt G, Danhol M. Pk/pd modeling of reversal of neuromuscular blockade by a chemically optimized cyclodextrin (abstract). Clin Pharmacol Ther 2004;75:80.

11. Ploeger BA, Houwiiig H, Bom A, van Lersel T, Zollinger D, Danliof M. The reversal of rucuronium-induced neuromuscular block by the cyclodextrin Org 25069: model development and validation. Poster presented at the Annual Meeting of the Population Approach Group in Europe; June 2004,Upsala, Sweden.

12. Miller S, Bom AH. Org 25969 causes selective reversal of neuromuscular blockade induced by steroidal NMBs in the mouse hemidiaphragm preparation (abstract). Eur J Anesthesiol 2001;18:100.

13. Mason R, Bom A. Org 25969 causes selective reversal of neuromuscular block induced by steroidal NMBs in anaesthetized guinea pigs (abstract). Eur J Anaesthesiol 2001;18:100.

14. Hope F, Bom A. Org 25969 reverses rocuronium-induced neuromuscular blockade in the cat without important hemodynamic effects (abstract). Eur J Anesthesiol 2001:18:100.

15. Van FgmontI J, van de Pol F, Booij L, Bom A. Neuromuscular blockade induced by steroidal NMBs can be rapidly reversed by Org 23969 in anaesthetized monkey and cats (abstract). Eur J Anaesthesiol 2001;18:100.

16. De Boer HD, Van Egmond J. Reversal of profound rocuronium neuromuscular blockade by sugammadex. Anesthesiology 2003;99:632-637.

17. Miller S, Bom AH. Org 25969 causes selective reversal of neuromuscular blockade induced by steroidal NMBs in ihe mouse hemidiaphragm preparation (abstract). Eur J Anesthesiol 2001;18:100.

18. Gijsenbergh F, Ramael S, De Bruyn S, Reilbergen H, van Lersal T. Preliminar assessment of Org 25969 as a reversal agent for rocuronium in heatlhy male volunteers (abstract). Anesthesiology 2002:A1008.

19. Gijsenbergh F, Ramael S, Houwing N, van Lersel T. First human exposure to Org 25969: a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005;103:695-703.

20. Shields M, Giovannelli M, Moppett L, Mahajan RR, Mirakhur RK. Deep neuromuscular block with Org 25969. Poster presented at the European Society of Anesthesia Congress; May 2005; Vienna, Austria.

21. Shields M, Giovannelli R, Mirakhur RK, Moppeu L, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for the antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006;96:36-43.

22. Khunl-Brady K, Rex C, Kjacr CC, Larsen PB, Prins ME, Puhringer F. Reversal of high dose rocuronium with Org 25969, Poster presented at the European Society of Anesthesia Congress: May 2005; Vienna. Austria.

23. Vanacker B, Vermeyen K, Struys MRF. Reversal by Org 25969 is not affected by sevoflurane when compared with propofol. Poster presented at the European Society of Anesthesia Congress; May 2005; Vienna, Austria.

24. Suy K, Morias K, Hans P, Heeringa M, Denmeyer I. Fast, effective and safe reversal of rocuronium and vecuronium-induced moderate neuromuscular block by the selective relaxant binding agent Org 25969, Poster presented at the American Society of Anesthesiologists Annual Meeting; October 2005; Atlanta, Ga.

25. de Boer H, Marcus M, Schouten I, Heeringa M. Reversal of rocuronium-induced (1.2 mg/kg) neuromuscular block by Org 25969: a multi-center dose finding and safety study. Poster presented at the American Society of Anesthesiologists. Annual Meeting; October 2005; Atlanta, Ga.

26. Naguib M. Sugammadex: Another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007;104: 575-581.

27. Sorgenfrei IIF, Norrild K, Larsen PB. Reversal of profound rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006;104:667-674.

28. Shields M, Giovanenelli M, Mirakhur RK. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium induced neuromuscular block. Br J Anaesth 2006;96:201-206.

29. Organon International, Organon reports positive results from phase III studies with novel agent to reverse muscle relaxation in anesthesia (press release) Available at http://www.organon.com/news/press_release/2005_05_31_organon_reports_positive_results_from_phase_II_studies_with_novel_agent_o_reverse_muscle_relaxation_in_anesthesia.asp. Accessed May 26, 2005.